bioMerieux (FR:BIM) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
bioMerieux has received FDA clearance for its VIDAS® TBI test, designed to improve the management of patients with mild traumatic brain injury by predicting the absence of intracranial lesions and potentially reducing unnecessary brain scans. The test, which measures specific biomarkers in the blood, could streamline the triage process in emergency settings and is set for a commercial launch in the US in the second half of 2024.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.